|
|
.
See Category: Neoplasms
ICD-10 (CM) Code and Descriptor
|
C67.8 |
Malignant neoplasm of overlapping sites of bladder
|
C678 utilizaton on OPPS claims.*
Primary
ICD10 Code |
ICD10
Position 2 |
ICD10
Position 3 |
ICD10
Position 4 |
ICD10
Position 5 |
ICD10
Position 6 |
ICD10
Position 7 |
ICD10
Position 8 |
ICD10
Position 9 |
ICD10
Position 10 |
| 60.57%
|
25.48%
|
6.68%
|
2.68%
|
1.54%
|
1.02%
|
0.62%
|
0.43%
|
0.29%
|
0.20%
|
* Medicare Part A utilization data is derived from the 100% 2023 Outpatient (Fee-for-Service) Standard Analytical File.
Commonly Associated Procedure Codes for C67.8*:
| CPT |
Description |
Number of Claims |
Sum Performed |
|
G0463
|
HOSPITAL OUTPT CLINIC VISIT |
13,282
|
13,359
|
|
85025
|
COMPLETE CBC W/AUTO DIFF WBC |
12,204
|
12,232
|
|
80053
|
COMPREHEN METABOLIC PANEL |
11,221
|
11,221
|
|
36415
|
COLL VENOUS BLD VENIPUNCTURE |
11,211
|
11,252
|
|
J3010
|
FENTANYL CITRATE INJECTION |
6,897
|
11,671
|
|
J2405
|
ONDANSETRON HCL INJECTION |
6,195
|
29,264
|
|
51720
|
TREATMENT OF BLADDER LESION |
5,954
|
5,954
|
|
J2704
|
INJ, PROPOFOL, 10 MG |
5,828
|
136,153
|
|
Q9967
|
LOCM 300-399MG/ML IODINE,1ML |
4,995
|
461,901
|
|
88112
|
CYTOPATH CELL ENHANCE TECH |
4,797
|
4,947
|
|
J1100
|
DEXAMETHASONE SODIUM PHOS |
4,752
|
34,756
|
|
88307
|
TISSUE EXAM BY PATHOLOGIST |
4,549
|
5,672
|
|
77386
|
NTSTY MODUL RAD TX DLVR CPLX |
4,358
|
4,362
|
|
J0690
|
CEFAZOLIN SODIUM INJECTION |
4,099
|
16,238
|
|
52000
|
CYSTOURETHROSCOPY |
3,837
|
3,837
|
|
80048
|
METABOLIC PANEL TOTAL CA |
3,603
|
3,611
|
|
96413
|
CHEMO IV INFUSION 1 HR |
3,579
|
3,579
|
|
J9201
|
IN GEMCITABINE HCL NOS 200MG |
3,495
|
25,808
|
|
A9270
|
NON-COVERED ITEM OR SERVICE |
3,489
|
8,289
|
|
J9030
|
BCG LIVE INTRAVESICAL 1MG |
3,412
|
142,957
|
* Derived from 100% 2021 Outpatient (Fee-for-Service) Standard Analytical File.
C67.8 related to the following DRG Codes:
656-658
686-688
|
